» Authors » Michael A Henderson

Michael A Henderson

Explore the profile of Michael A Henderson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 85
Citations 1112
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Mor E, Mor-Hadar D, Henderson M, Snow H, Gyorki D
ANZ J Surg . 2025 Mar; PMID: 40071744
Purpose: Retroperitoneal sarcomas (RPS) present a surgical challenge due to their complex anatomical relationships to organs and vascular structures. In this limited case series, we reconstructed the tumour beds of...
2.
Mor E, Baker B, Henderson M, Lazarakis S, Mitchell C, Speakman D, et al.
ANZ J Surg . 2024 Sep; 94(12):2150-2158. PMID: 39253994
Purpose: Radiation-induced angiosarcoma (RIAS) of the breast is a rare tumour with high rate of local recurrence. The aim of this study is to evaluate the outcome of radical resections....
3.
Mor E, Tejman-Yarden S, Mor-Hadar D, Assaf D, Eifer M, Nagar N, et al.
Ann Surg Oncol . 2024 Jun; 31(10):7198-7205. PMID: 38898325
Background: Retroperitoneal sarcomas (RPSs) present a surgical challenge, with complex anatomic relationships to organs and vascular structures. This pilot study investigated the role of three-dimensional (3D) augmented reality (3DAR) compared...
4.
Jobson D, McCormack C, Mar V, Tam C, Henderson M
Br J Haematol . 2022 Mar; 197(3):320-325. PMID: 35286715
With new, effective treatments for chronic lymphocytic leukaemia (CLL) the impact of second malignancies is increasingly important. We performed a retrospective case-controlled study examining the effect of CLL and its...
5.
Scolyer R, Atkinson V, Gyorki D, Lambie D, OToole S, Saw R, et al.
Pathology . 2021 Dec; 54(1):6-19. PMID: 34937664
Targeted therapy (BRAF inhibitor plus MEK inhibitor) is now among the possible treatment options for patients with BRAF mutation-positive stage III or stage IV melanoma. This makes prompt BRAF mutation...
6.
Downs J, Subramaniam S, Henderson M, Paton E, Spillane A, Mathy J, et al.
J Surg Oncol . 2021 Aug; 124(8):1544-1550. PMID: 34406652
Background: The evidence-based management of melanoma patients with a positive sentinel lymph node biopsy (SLNB) has undergone a dramatic shift following publication of practice-changing surgical trials demonstrating no melanoma-specific survival...
7.
Carr M, Sun J, Kroon H, Miura J, Beasley G, Farrow N, et al.
Ann Surg Oncol . 2020 Sep; 27(13):5107-5118. PMID: 32918177
Background: Isolated limb infusion (ILI) is a minimally invasive procedure for delivering high-dose chemotherapy to extremities affected by locally advanced or in-transit melanoma. This study compared the outcomes of melanoma...
8.
Koo E, Henderson M, Dwyer M, Skandarajah A
Asia Pac J Clin Oncol . 2020 Sep; 16(6):363-371. PMID: 32894009
Aims: Survivors of childhood, adolescent, and young adulthood malignancies have an increased risk of subsequent primary malignancies, particularly after exposure to therapeutic radiation. This study aims to evaluate the mode...
9.
Kenyon-Smith T, Kroon H, Miura J, Teras J, Beasley G, Mullen D, et al.
Eur J Surg Oncol . 2020 Aug; 46(11):2140-2146. PMID: 32739218
Introduction: Isolated limb infusion (ILI) is a minimally-invasive procedure for delivering high-dose regional chemotherapy to treat melanoma in-transit metastases confined to a limb. The aim of this international multi-centre study...
10.
Toppi J, Tham Y, Webb A, Henderson M, Rischin D, Magarey M
ANZ J Surg . 2020 Jul; 90(7-8):1391-1395. PMID: 32627359
Background: Surgery is the primary treatment for patients with recurrent head and neck cutaneous squamous cell carcinoma (cSCC) who have previously been treated by definitive surgery and radiotherapy. There are...